Healthcare
Pharma Mar, S.A.(PHMMF)
Live Price
Offline$79.49
+0.00% today
1Y Change
-14.13%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- $1.66B
- Revenue Growth
- +26.6%
- EPS Growth
- +192.6%
- Dividend Yield
- 0.8%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pharma Mar, S.A. (PHMMF) is a Healthcare stock with a market cap of $1.66B and listed on OTC. The stock last traded around $79.49 and down 14.1% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +26.6%, EPS growth of +192.6%, a dividend yield of 0.8%. What stands out right now is revenue +26.6%, EPS +192.6%, free cash flow +561.2% with operating margin 24.9% and ROIC 17.6%. The dividend is present but secondary, with a yield around 0.8%. Valuation sits in the middle of the pack at P/E 22.0 and price/sales 7.5. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines PHMMF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+26.6% vs +7.6% peer median
Operating Margin
Above sector median
+24.9% vs +19.4% peer median
P/E
Below sector median
22.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +26.6% and EPS at +192.6%, with operating margin around 24.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.8%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Feb 27, 2026 | +8.6% | +0.0% | +0.0% | +3.9% |
2025 Jul 30, 2025 | +4399.1% | +0.0% | +0.0% | +6.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHMMF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PHMMF Max Drawdown
-28.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PHMMF and SPY.
Company Overview
Pharma Mar, S.A.
Other OTC
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
- Leadership
- Jose Maria Fernandez Sousa-Faro
- IPO Date
- Feb 23, 2016
- Employees
- 500
- Street Address
- Avenida de los Reyes, 1
- Mailing
- Madrid, 28770
- Region
- Madrid, ES
- Reporting Currency
- USD
- Investor Line
- 34 91 846 60 00
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 22.0
- EV/EBITDA
- 25.9
- Price/Sales
- 7.5
- Price/Book
- 6.6
Growth
- Revenue
- +26.6%
- EPS
- +192.6%
- Free Cash Flow
- +561.2%
Profitability
- Gross Margin
- 92.6%
- Operating Margin
- 24.9%
- Net Margin
- 33.9%
- ROE
- 35.4%
- ROIC
- 17.6%
Balance Sheet
- Debt/Equity
- 0.20
- Current Ratio
- 3.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.